Indole-3-propionic acid connects gastrointestinal impairment to diabetic retinopathy: a potential biomarker and innovative treatment strategy
-
By
-
May 1, 2026
Objective:
To investigate the role of indole-3-propionic acid (IPA) and tryptophan (Trp) metabolism in diabetic retinopathy (DR) and explore potential therapeutic strategies, including nutraceutical supplementation and engineered probiotics.
Key Findings:
- IPA levels are significantly lower in individuals with DR compared to diabetics without retinopathy, indicating a potential biomarker.
- Supplementation with IPA mitigated diabetes-induced gut dysfunction and prevented DR in T2D mice, supporting its therapeutic potential.
- IPA enhances pregnane X receptor expression, reducing inflammation in gut and retinal epithelial cells, which may contribute to improved barrier function.
Interpretation:
Impaired Trp metabolism and reduced IPA levels contribute to the pathogenesis of DR, suggesting that IPA could serve as a biomarker and therapeutic target for early intervention.
Limitations:
- The study primarily utilized murine models, which may not fully replicate human conditions, necessitating caution in extrapolating results.
- Further clinical studies are needed to validate IPA as a biomarker in human populations and assess its therapeutic efficacy.
Conclusion:
Restoring gut barrier function and modulating inflammation through IPA supplementation presents a novel, safe, and cost-effective strategy for managing diabetic retinopathy, with implications for clinical practice and future research.
